An insight on promising strategies hoping to cure HIV-1 infection by targeting Rev protein-short review.
Pharmacol Rep
; 73(5): 1265-1272, 2021 Oct.
Article
en En
| MEDLINE
| ID: mdl-33840054
Human immunodeficiency virus-1 (HIV-1) infection remains to be one of the major threats throughout the world. Many researchers are working in this area to find a cure for HIV-1. The group of the FDA approved drugs which are currently used against HIV-1 in the clinical practice include nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors (InIs), and protease inhibitors (PIs). Fixed dose combinations (FDCs) of these drugs are available and are used as per the anti-retroviral therapy (ART) guidelines. Despite these, unfortunately, there is no cure for HIV1 infection to date. The present review is focused upon describing the importance of a post-transcriptional regulatory protein "Rev", responsible for latent HIV-1 infection as a possible, and promising therapeutic target against HIV-1.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Infecciones por VIH
/
VIH-1
/
Sistemas de Liberación de Medicamentos
/
Fármacos Anti-VIH
/
Productos del Gen rev del Virus de la Inmunodeficiencia Humana
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Revista:
Pharmacol Rep
Asunto de la revista:
FARMACOLOGIA
Año:
2021
Tipo del documento:
Article
País de afiliación:
India
Pais de publicación:
Suiza